CClinicalTrials.gg
Status unknownNCT03218306SPIDERUpdated Oct 26, 2017

Surgical Pleth Index (SPI) Versus Standard Clinical Approach Analgesia

An interventional study of Surgical Pleth Index and Clinical guidance in Anesthesia, Pain and Surgery, sponsored by University of Cagliari. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-10-26.

Sponsored by University of Cagliari · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The study is aimed at confronting a surgical pleth index based protocol for intraoperative analgesia in a desflurane based general anesthesia for thyroidectomy, versus a standard clinical approach. A reduction in analgesic consumption and improvement in hemodynamics are expected.

02

Conditions studied

  • Anesthesia
  • Pain
  • Surgery

Keywords

  • SPI
  • Remifentanil
  • Target controlled infusion
03

In context

Lead sponsor

University of Cagliari is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18\<age\<80 years
  • American society of anesthesiology (ASA) physical status I -II
  • 6 hrs fasting

Exclusion criteria

Exclusion Criteria:

  • Arrhythmia or Pacemaker
  • Central or peripheral nervous system or muscular disease
  • Drugs active on autonomous nervous system (eg clonidine)
  • Obesity (BMI >35)
  • Chronic Pain
  • Addictions or central nervous acting drugs use
  • Hypertension (if not treated)
  • Connective tissue disease
  • Pregnancy
  • Allergy or hypersensitivity to study drugs
  • QT prolongation
  • Absence of inclusion criteria
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    SPI guided analgesia

    SPI ≤ 10 percentual points over the post-induction/pre-surgical incision value

    Device: Surgical Pleth Index

  • Active comparator
    Clinical Guided Analgesia

    No SPI guidance

    Other: Clinical guidance

Interventions

  • DeviceSurgical Pleth Index

    Effector site concentration of remifentanil based on SPI

  • OtherClinical guidance

    Effector site concentration of remifentanil based on hemodynamic data

06

What researchers measure

Primary outcomes

  1. Remifentanil consumption

    Cumulative remifentanil consumption throughout surgery

    Time frame: Intraoperative

Secondary outcomes

  1. Hemodynamics

    Cumulative number of episodes of hypotension or hypertension or brady/tachycardia

    Time frame: intraoperative

  2. Desflurane

    Cumulative consumption of desflurane (ml) as measured by datex ohmeda aysis ventilator

    Time frame: intraoperative

  3. Extubation delay

    Timespan between end of surgery and extubation

    Time frame: intraoperative

  4. Post-operative analgesia 1

    Evaluate the total consumption of analgesics in the first 24 hours after surgery

    Time frame: 24 hr post operative

  5. Post-operative analgesia 2

    measure pain in the first post-operative day

    Time frame: 24 hr post operative

  6. Adverse reactions

    Nausea and vomiting in the 1st post-operative day

    Time frame: 24 hr post operative

  7. Patient satisfaction

    Evaluate on a 0-4 numeric scale patient satisfaction

    Time frame: 24 hr post operative

07

Study locations

1 of 1 sites recruiting
  • Policlinico Duilio Casula
    Monserrato, Cagliari 09072, Italy
    • Paolo Mura, MD · Contact · mura_paolo@hotmail.com · +39 3476527512
    • Paolo Onida, MD · Principal investigator
    • Paolo Mura, MD · Sub investigator
    • Tiziana Cabras, RN · Sub investigator
    • Riccardo Pili, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03218306
Lead sponsor
University of Cagliari
Responsible party
Prof. Gabriele Finco (Professor of Anesthesiology and Intensive Care, University of Cagliari) — Principal investigator
First posted
Jul 14, 2017
Start date
Oct 23, 2017
Primary completion
Oct 1, 2018 (estimated)
Completion
Dec 1, 2018 (estimated)
Last update
Oct 26, 2017

Study contacts

Paolo Onida, MD
Contact
paolo.onida80@gmail.com
+3907051096543
Paolo Mura, MD
Contact
mura_paolo@hotmail.com
+3907051096543
Gabriele Finco, MD
study director · University of Cagliari

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion